Evolus (EOLS) Long-Term Deferred Tax (2022 - 2023)
Evolus (EOLS) reported Long-Term Deferred Tax of $9.2 million for Q4 2023, down 25.76% on a YoY basis from $12.3 million in Q4 2022, and down 25.76% quarter-over-quarter from $12.3 million in Q4 2022.
Evolus (EOLS) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
Evolus has reported Long-Term Deferred Tax for 2 years, with the latest figure at $9.2 million in Q4 2023.
- For the quarter ending Q4 2023, Long-Term Deferred Tax fell 25.76% year-over-year to $9.2 million; the trailing twelve-month figure through Dec 2023 stood at $9.2 million (down 25.76% YoY), and the FY2023 full-year result was $9.2 million, down 25.76% from the prior year.
- Long-Term Deferred Tax for Q4 2023 stood at $9.2 million, down from $12.3 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $12.3 million in Q4 2022, with the low at $9.2 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | Evolus | 435.45 Mn | 385.65 Mn | 48.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 9.16 Mn |
| Dec 31, 2022 | 12.34 Mn |